Stock XLS XLIFE SCIENCES AG
Add to a list
To use this feature you must be a member
Log inSign up

Xlife Sciences AG Stock BOERSE MUENCHEN

Equities

XLS

CH0461929603

Biotechnology & Medical Research

Real-time BOERSE MUENCHEN
Other stock markets
 01:43:00 2022-02-10 pm EST 		5-day change 1st Jan Change
41.8 EUR -0.48% Intraday chart for Xlife Sciences AG -.--% -3.69%
Apr. 23 Xlife Sciences Posts Higher FY23 Profit; Revenue Falls MT
Feb. 29 Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2022 1.03M 1.14M 1.06M Sales 2023 988K 1.1M 1.02M Capitalization 279M 310M 287M
Net income 2022 14M 15.58M 14.39M Net income 2023 14M 15.58M 14.39M EV / Sales 2022 211 x
Net Debt 2022 60.41M 67.21M 62.08M Net Debt 2023 56.48M 62.84M 58.05M EV / Sales 2023 339 x
P/E ratio 2022
14.9 x
P/E ratio 2023
24 x
Employees 17
Yield 2022 *
-
Yield 2023
-
Free-Float 49.77%
More Fundamentals * Assessed data

Chart Xlife Sciences AG

Dynamic Chart

Latest news about Xlife Sciences AG

Xlife Sciences Posts Higher FY23 Profit; Revenue Falls MT
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Switzerland’s Xlife Sciences, Abu Dhabi Expand Existing Life Sciences Partnership MT
Xlife Sciences, Quant Team Up to Develop Biomarkers for Kidney Diseases Detection MT
Xlife Sciences to Sell Portfolio Company to 4D Lifetec MT
Xlife Sciences AG acquired 20% stake in 4D Lifetec AG for CHF 23.3 million. CI
Xlife Sciences Loss Narrows in H1; Revenue Declines MT
Xlife Sciences AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Xlife Sciences AG Signs Memorandum of Understanding with the Regulator of the Healthcare Sector in the UAE, the Department of Health - Abu Dhabi CI
Xlife Sciences AG Announces Bernhard Scholz Will Not Stand for Re-Election CI
Xlife Sciences Posts Lower FY22 EPS; Revenue Increases MT
Xlife Sciences AG Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Xlife Sciences Portfolio Company Receives European Patent for Biological Tissue Generation Method MT
Xlife Sciences' Portfolio Company To Research Therapy For Amyotrophic Lateral Sclerosis MT
Xlife Sciences AG Launches Project to Research a Potential Therapy for Amyotrophic Lateral Sclerosis CI
More news

Press releases Xlife Sciences AG

Xlife Sciences AG: Successful General Assembly and New Trading Hours on the Sparks Segment of SIX EQ
Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness EQ
Xlife Sciences : Praesentation PU
Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH EQ
Xlife Sciences : Praesentation PU
More press releases

News in other languages on Xlife Sciences AG

Xlife Sciences AG: Erfolgreiche Generalversammlung und neue Handelszeiten am Sparks-Segment der SIX
Xlife Sciences AG: Erfolgreiche Generalversammlung und neue Handelszeiten am Sparks-Segment der SIX
Xlife-Gesellschaft X-Nuclear Diagnostics erreicht Markreife in Leberdiagnostik
Xlife Science signale des accomplissements de sociétés en portefeuille
Xlife Sciences AG meldet Erfolg in der Leberdiagnostik – x-nuclear diagnostics GmbH erreicht Marktreife
More news

Quotes and Performance

1 day-0.48%
Current month-3.69%
Current year-3.69%
More quotes

Highs and lows

3 years
41.80
Extreme 41.8
53.00
5 years
24.00
Extreme 24
60.00
10 years
24.00
Extreme 24
60.00
More quotes

Managers and Directors - Xlife Sciences AG

Managers TitleAgeSince
Oliver Baumann CEO
 Chief Executive Officer - 19-06-30
Carl von Halem DFI
 Director of Finance/CFO - 21-11-30
Alexander Zink CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Christian Faber CMP
 Compliance Officer - 19-09-11
Mark Müller BRD
 Director/Board Member - 18-10-24
Oliver Baumann CEO
 Chief Executive Officer - 19-06-30
More insiders

Company Profile

Xlife Sciences AG is a Switzerland-based biotechnology company. The Company focuses on investing in technologies in the life science industry. It supports researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. The Company offers its investors direct access to the further development of technologies at a very early stage. The Company cooperates with industrial partners and universities.
Sector
Biotechnology & Medical Research
Calendar
2024-09-18 - Q2 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+16.59% 44.44B
LONZA GROUP AG Stock Lonza Group AG
+41.11% 40.03B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-10.62% 37.68B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+29.92% 31.46B
CELLTRION, INC. Stock Celltrion, Inc.
-9.23% 27.29B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.34% 26.29B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+41.53% 13.8B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.49% 12.46B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-7.40% 11.26B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. XLS Stock
  4. XLS Stock